|
|
|
In 1971, Warren Eisenberg and Leonard Feinstein opened a small store in Springfield, New Jersey called “Bed 'n Bath.” Today, our 65,000+ associates support over 1,500 retail locations, “Business-to-Business” operations, and online destinations for products, solutions and services. We currently operate in the United States, Canada, Mexico and Puerto Rico. Our Corporate offices are located in Union, New Jersey, right down the road from our first store.
|
Ms. Mary A. Winston
Interim CEO & Director Bed Bath & Beyond Inc.650 Liberty Avenue Union, NJ 07083 United States 908-688-0888 http://www.bedbathandbeyond.com NASDAQ BBBY |
|
Elliot Bernstein founded Bel Fuse Inc. in 1949 as a maker of automobile fuses. Bel has created and delivered power, protection and connectivity solutions for major customers ever since—from the early days of RCA television sets and IBM mainframe computers to the contemporary era of Oracle, Facebook and Tesla. Publicly held since 1967, Bel has grown and thrived under the continuous leadership of the Bernstein family. It operates manufacturing sites, sales offices and design centers, 32 in all, across North America, Europe and Asia. President and CEO Dan Bernstein puts it more simply: “As new technologies evolve, Bel evolves with them.” Since 1998, Bel has acquired fourteen companies to help build out the Power | Protect | Connect portfolio that exists today. Of these acquisitions, six of them were divestitures from large conglomerates including Emerson, ABB, TE, Safran, Insilco and Lucent.
|
Mr. Daniel Bernstein
President Bel Fuse Inc 206 Van Vorst Street Jersey City, NJ 07302 United States 201-432-0463 http://www.belfuse.com NASDAQ BELFA |
|
BIO-key is a pioneer and innovator in one, we are recognized as a leading developer of fingerprint biometric authentication and security solutions. Our roots can be traced to 1993. Thus, we have a long track record of supporting biometric authentication projects and developing healthy customer relationships. We don’t rest on our laurels, and we continue to grow and introduce innovative new products such as our compact line of fingerprint scanners for Windows Hello and TouchLock a line of fingerprint and Bluetooth enabled padlocks and bicycle locks (view summary of our patents). We are continually striving to identify new use cases for our fingerprint biometric technology.
|
Mr. Michael W. DePasqual
Chairman BIO-key International, Inc Building A Suite E 3349 Highway 138 Wall, NJ 07719 United States 732-359-1100 http://www.bio-key.com NASDAQ BKYI |
|
For more than 65 years, Blonder Tongue Laboratories, Inc. has provided our customers with innovative and cost-effective solutions for their media needs. We meet every challenge with a combination of ingenuity, creativity, and practical experience, ensuring that all of our products hold superior quality for today, and tomorrow.
|
Mr. Robert J. Pallé Jr.
CEO Blonder Tongue Laboratories, Inc One Jake Brown Road Old Bridge, NJ 08857 United States 732-679-4000 http://www.blondertongue.com NYSE BDR |
|
Cambrex is the small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. Enjoy working with our experts to accelerate your small molecule therapeutics into the market
|
Mr. Steven M. Klosk
President Cambrex Corporation One Meadowlands Plaza East Rutherford, NJ 07073 United States 201-804-3000 http://www.cambrex.com NYSE CBM |
|
Campbell Soup Company (NYSE:CPB) is a multi-national food company headquartered in Camden, N.J., with annual sales of approximately $8 billion. The Company makes a range of high-quality soups and simple meals, beverages, snacks and packaged fresh foods. Campbell is driven and inspired by our purpose: Real food that matters for life’s moments. For generations, people have trusted Campbell to provide authentic, flavorful and readily available foods and beverages that connect them to each other, to warm memories, and to what’s important today.
|
Mr. Mark A. Clouse
President Campbell Soup Company 1 Campbell Place Camden, NJ 08103 United States 856-342-4800 http://www.campbellsoupcompany.com NYSE CPB |
|
Cancer genetics is a precision medicine company focused in oncology. We've been fortunate to have some of the world's most unique and innovative companies as our customers. Companies like Gilead, Glaxo-Smith Kline, and Astra Zeneca. In addition, Cancer centers such as Sloan Kettering, Beth Israel, Dana Farber, USC Keck School of Medicine are all collaborators, partners, and customers for us today. Cancer Genetics was founded in 2000 by some of the world's best Cancer scientists from Sloan Kettering. Our ability to diagnosed cancer, provide data about the potential prognosis for the patient and map that to a therapeutic option is very compelling and is a critical ingredient to enable precision medicine. Today our company is involved in nearly a 100 clinical trials, helping select patients, stratify patients, monitor patients and manage these large complex multi-arm oncology trials.
|
Mr. John A. Roberts
President Cancer Genetics Inc 201 Route 17 North 2nd Floor Rutherford, NJ 07070 United States 201-528-9200 http://www.cancergenetics.com NASDAQ CGIX |
|
Cantel is a global company dedicated to delivering innovative infection prevention products and services for patients, caregivers, and other healthcare providers, which improve outcomes and help save lives. Through an expansive portfolio of endoscopy, water purification and filtration, and healthcare disposables, Cantel provides high-quality infection prevention solutions and unsurpassed service, touching millions of patients around the world each year.
|
Mr. George L. Fotiades
President Cantel Medical Corp 150 Clove Road 9th Floor Little Falls, NJ 07424 United States 973-890-7220 http://www.cantelmedical.com NYSE CMD |
|
Catalent, the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, announced they have entered into a definitive agreement under which Catalent will acquire Paragon. Paragon brings specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used delivery system for gene therapy, as well as unique capabilities in GMP plasmids and lentivirus vectors.
For over 25 years, Paragon has partnered with some of the world’s best biotech and pharma companies to develop and manufacture products based on transformative technologies, including AAV and other gene therapies, next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic proteins, and other complex biologics. |
Mr. John R. Chiminski
Chairman Catalent, Inc 14 Schoolhouse Road Somerset, NJ 08873 United States 732-537-6200 http://www.catalent.com NYSE CTLT |
|
Celgene is a global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. At Celgene, we seek to deliver truly innovative and life-changing medicines that make a difference in the lives of patients worldwide, reduce burden on healthcare systems and help economies grow. As committed as we are to clinical accomplishment and innovation, we are equally committed to patient support, which is a guiding principle at Celgene.
|
Mr. Mark J. Alle
Chairman Celgene Corporation 86 Morris Avenue Summit, NJ 07901 United States 908-673-9000 http://www.celgene.com NASDAQ CELG |